Can stem cell therapy really treat multiple sclerosis?
Can stem cell therapy really treat multiple sclerosis? August 18, 2016 Source: Bio Valley Recently, according to Daily Mail, Eric Thompson, a patient with multiple sclerosis (MS), stood up from the wheelchair several days after the treatment of hematopoietic stem cells (Haematopoietic StemCells) and was able to walk normally. Tungmpson and his family raised £40,000 and started the therapy in Mexico, which was not able to receive positive treatment from the National Health Service (NHS). Thompson's treatment is called autologous hematopoietic stem cell transplantation (AHSCT). The first step is to take stem cells from the patient's bone marrow or blood. When the patient undergoes concentrated chemotherapy to weaken the function of the immune system, The stem cells extracted from the patient's body are reinjected into the patient's body in order to restart the patient's immune system. The use of concentrated high-dose chemotherapy and the transplantation process are often difficult processes during the course of therapy. According to data from the UK Cancer Research Center, donor stem cell transplants are often used to treat many types of cancer, including leukemias, lymphomas, and myeloma. However, autologous hematopoietic stem cell transplantation is now recommended as a treatment for multiple sclerosis. premature. Although the NHS is currently unable to provide this therapy, the British Multiple Sclerosis Society reported that many studies have used their own hematopoietic stem cell transplantation therapy to treat multiple sclerosis, and researchers have shown that this therapy has great prospects. In patients treated with therapies, the recurrence rate of the disease is reduced, the recovery of the patient is relatively stable, and even the disability symptoms of some patients are reversed. However, the Multiple Sclerosis Association emphasizes that this may not apply to every patient, and that the treatment may be “aggressive†and pose significant risks. Clinical Trials A series of treatments using autologous hematopoietic stem cell transplantation to treat multiple sclerosis are ongoing, including the ASTIMS trial conducted in March 2015. This trial has 21 patients with relapsing-remitting multiple sclerosis (patients have different Disease symptoms) and patients with progressive multiple sclerosis (patient disability is not due to recurrence of the disease); the recurrence rate of patients receiving autologous hematopoietic stem cell transplantation therapy compared with patients treated with the drug mitoxantrone The name has dropped. Mitoxantrone is a typical chemotherapy that can be used as a disease modification therapy to reduce the number of patients with multiple sclerosis, but the researchers say that some patients who receive their own hematopoietic stem cell transplantation therapy tend to Experienced serious side effects such as thrombocytopenia, neutropenia, infection, and liver toxicity, and two of them also suffered from life-threatening conditions, including sepsis, severe infection, and survival rate of bone marrow stem cell transplantation. Low and complete failure of treatment. The UK is conducting randomized clinical trials in one of MIST countries (multiple countries including the United Kingdom, the United States, Sweden and Brazil), and many patients receiving their own hematopoietic stem cell transplantation therapy have shown positive results, and patients express their bodies. The symptoms of multiple sclerosis have been significantly improved and reversed, and MRI scans have also shown evidence of no active disease in the patient's body. All clinical trial results will be published in 2017, and many patients are also looking forward to positivity. The data will be announced soon. The UK's research center is located at the Royal Hallamshire Hospital. Some clinical trial patients also appeared in the BBC's Panorama Program in January 2016. The results of a clinical trial of autologous hematopoietic stem cell transplantation in Canada present a significant change in disease recurrence and disease activity in patients with multiple sclerosis, with approximately 70% of patients showing signs of complete cessation of disease progression. However, one of the patients undergoing trials died of liver failure, which may be caused by a side effect of the therapy; the researchers emphasized that these therapies must be considered in patients with progressive multiple sclerosis who must be active in activities. Related risks. The story of patient Eric Thompson has greatly promoted the use of autologous hematopoietic stem cell transplantation therapy in patients with multiple sclerosis, but at the same time we should not ignore the risks and costs of the therapy; multiple sclerosis association biomedicine The director of the institute, Sorrel Bickley, believes that this positive therapy is often accompanied by a certain risk, which needs to be reconfirmed by experts and should also be implemented at the certification center. We are not aware of the long-term effects of our own hematopoietic stem cell transplantation therapy, which underscores the importance of late clinical trials. Qingdao Beautiful Skin Biotechnology Co., Ltd , https://www.hafilleresthetic.com